Peter J. Collum
Director of Finance/CFO chez REDX PHARMA PLC
Profil
Peter J.
Collum is currently the Chief Financial Officer at Redx Pharma Plc.
Prior to this, he was the Chief Financial & Business Officer at Pharnext SA from 2019 to 2021.
He was also a Partner at MTS Health Partners LP from 2009 to 2019.
Before that, he held Principal positions at Bank of America Corp.
from 2003 to 2009 and at Hoffmann-La Roche, Inc. from 1996 to 2000.
Collum received his undergraduate degree from Rutgers State University of New Jersey and his MBA from The University of Chicago Booth School of Business.
Postes actifs de Peter J. Collum
| Sociétés | Poste | Début |
|---|---|---|
| REDX PHARMA PLC | Director of Finance/CFO | 05/05/2021 |
Anciens postes connus de Peter J. Collum
| Sociétés | Poste | Fin |
|---|---|---|
| PHARNEXT SCA | Director of Finance/CFO | 01/04/2021 |
MTS Health Partners LP
 MTS Health Partners LP Investment Banks/BrokersFinance MTS Health Partners LP provides strategic and financial advisory services to healthcare companies from global corporations to venture backed businesses. Its strategic advisory alternatives include mergers, acquisitions, company sales, divestitures, recapitalizations, restructurings, general strategic advisory, financing oversight and oversight opinions. The firms financing solutions include traditional private convertible preferred issuances, cross-over focused convertible transactions, common stock and structured/convertible PIPEs, registered direct and acquisition financings, secondary sales, special situations, structured debt financings and royalty monetization. The company was founded by Curtis Scott Lane in 2000 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/06/2019 |
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Corporate Officer/Principal | 01/01/2009 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | 01/01/2000 |
Formation de Peter J. Collum
| Rutgers State University of New Jersey | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Finance |
| PHARNEXT SCA | Health Technology |
| REDX PHARMA PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
MTS Health Partners LP
MTS Health Partners LP Investment Banks/BrokersFinance MTS Health Partners LP provides strategic and financial advisory services to healthcare companies from global corporations to venture backed businesses. Its strategic advisory alternatives include mergers, acquisitions, company sales, divestitures, recapitalizations, restructurings, general strategic advisory, financing oversight and oversight opinions. The firms financing solutions include traditional private convertible preferred issuances, cross-over focused convertible transactions, common stock and structured/convertible PIPEs, registered direct and acquisition financings, secondary sales, special situations, structured debt financings and royalty monetization. The company was founded by Curtis Scott Lane in 2000 and is headquartered in New York, NY. | Finance |
